Stock BCT BRIACELL THERAPEUTICS CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages BriaCell Therapeutics Corp.

Equities

BCT

CA1079301091

Market Closed - Toronto S.E.
Other stock markets
 20:56:05 21/05/2024 BST 		5-day change 1st Jan Change
2.1 CAD +12.30% Intraday chart for BriaCell Therapeutics Corp. -26.57% -73.08%
05-20 Briacell Therapeutics Insider Bought Shares Worth $2,000,001, According to a Recent SEC Filing MT
05-15 BriaCell Therapeutics Prices $5 Million Offering; Shares Tumble MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Briacell Therapeutics Insider Bought Shares Worth $2,000,001, According to a Recent SEC Filing
BriaCell Therapeutics Prices $5 Million Offering; Shares Tumble
BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+? and Bria-PROS+? Clinical Candidates for Breast and Prostate Cancer
BriaCell to Showcase Latest Bria-IMT Data in Poster Presentations at 2024 AACR
BriaCell Therapeutics Corp. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024
BriaCell to Present Clinical Data in CNS Metastasis and Antibody-Drug Conjugate Resistant Breast Cancer at AACR Conference
BriaCell Therapeutics Corp. Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case
Briacell Therapeutics Corp. Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates Gmp Manufacturing
BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with "Eye-Bulging" Metastatic Breast Cancer
BriaCell Has Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients
BriaCell Therapeutics Corp. Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients
BriaCell Therapeutics Corp. Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate Refractory Patient Subset
BriaCell Therapeutics Corp. Reports Earnings Results for the First Quarter Ended October 31, 2023
BriaCell Highlights Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at Breast Cancer Symposium
BriaCell Therapeutics Corp. Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS
BriaCell Therapeutics Corp. Announces Anew Remarkable Responder in Phase 2 Study of the Bria-IMT Combination Regimen
BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS? IND
Top Premarket Gainers
BriaCell Therapeutics Corp. Reports Earnings Results for the Full Year Ended July 31, 2023
BriaCell Forms Medical Advisory Board of Breast Cancer Specialists to Advance Lead Oncology Candidate
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BCT Stock
  4. News BriaCell Therapeutics Corp.
  5. Other languages